

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM633590

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Innovus Pharmaceuticals, Inc.		03/19/2021	Corporation: NEVADA
Aytu BioScience, Inc.		03/19/2021	Corporation: DELAWARE
Semprae Laboratories, Inc.		03/19/2021	Corporation: DELAWARE
Aytu Therapeutics LLC		03/19/2021	Limited Liability Company: DELAWARE
Novalere, Inc.		03/19/2021	Corporation: DELAWARE
Aytu Consumer Health, Inc		03/19/2021	Corporation: DELAWARE
Supplement Hunt, Inc.		03/19/2021	Corporation: NEVADA
Delta Prime Savings Club, Inc.		03/19/2021	Corporation: NEVADA

## RECEIVING PARTY DATA

<b>Name:</b>	DEERFIELD MGMT, L.P., as Collateral Agent
<b>Street Address:</b>	345 Park Avenue South
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10010
<b>Entity Type:</b>	Limited Partnership: DELAWARE

## PROPERTY NUMBERS Total: 113

Property Type	Number	Word Mark
<b>Serial Number:</b>	88631225	ACC NEURITE COMPLEX
<b>Serial Number:</b>	87321960	ALLERVARX
<b>Serial Number:</b>	87365742	APEAZ
<b>Serial Number:</b>	87497489	ARTHRIVARX
<b>Serial Number:</b>	86724493	AYTU
<b>Serial Number:</b>	90160190	AYTUMUNE
<b>Serial Number:</b>	90160351	AYTUMUNE
<b>Serial Number:</b>	88843582	AYTUVIR
<b>Serial Number:</b>	88843583	AYTUVIR
<b>Serial Number:</b>	88843587	AYTUVIR
<b>Serial Number:</b>	90132694	AYTU CONSUMER HEALTH
<b>Serial Number:</b>	85967626	BEYOND HUMAN

TRADEMARK

Property Type	Number	Word Mark
Serial Number:	87605268	BEYOND HUMAN
Serial Number:	88356845	BEYOND HUMAN
Serial Number:	88378275	BHT
Serial Number:	88178462	BOSTON TOPICALS
Serial Number:	88230627	BREASTLIFT
Serial Number:	88230629	BREASTLIFT
Serial Number:	75469228	CARDIOTEK
Serial Number:	88040646	CARVANUM
Serial Number:	86041180	CECLOR
Serial Number:	88381293	DELTA PRIME SAVINGS CLUB
Serial Number:	88429943	DHTCARE
Serial Number:	87717770	DIABASENS
Serial Number:	88838768	D DIABASENS
Serial Number:	88877573	DIGERYXIN
Serial Number:	88957866	DIGERYXIN OTC
Serial Number:	85914704	EJECTDELAY
Serial Number:	88359960	EURYCO-8
Serial Number:	88658569	EURYCO-10
Serial Number:	88830315	E EURYCO-10
Serial Number:	88746003	FLEXILON
Serial Number:	88179840	FLOVINTRO
Serial Number:	87671266	FLUTICANEX
Serial Number:	87671340	FLUTICANX
Serial Number:	87262502	FLUTICARE
Serial Number:	87601188	FLUTICARE
Serial Number:	90485739	FORTEBEET
Serial Number:	88591106	FROM SCIENCE TO SOLUTION
Serial Number:	87617672	GLUCOGORX
Serial Number:	88838817	GLUCOGORX
Serial Number:	88065228	GLUCOGORX
Serial Number:	88885353	HEALIGHT
Serial Number:	77346838	HEALTHIFEET
Serial Number:	88498145	ICARESUP
Serial Number:	85412980	INNOVUS PHARMA
Serial Number:	87794483	INNOVUS PHARMA
Serial Number:	88331577	INNOVUS PHARMA
Serial Number:	88466887	INNOVUS PHARMA
Serial Number:	88597743	INNOVUS PHARMA

Property Type	Number	Word Mark
Serial Number:	88179847	IRACILXL
Serial Number:	88826450	KETOGORX
Serial Number:	88826515	KETOGORX
Serial Number:	90524780	M.A.C. DEFENSE
Serial Number:	85365008	MATERNA
Serial Number:	86724491	MIOXSYS
Serial Number:	87527180	MUSCLIN
Serial Number:	88057974	M MUSCLIN
Serial Number:	88228922	MZS
Serial Number:	87820415	MZS MELATONIN
Serial Number:	88506510	MZS SLEEPING AID
Serial Number:	87820758	MZS SLEEPING AID
Serial Number:	87684151	NASOVA
Serial Number:	87957369	NEURITERX
Serial Number:	86224631	NOVALERE
Serial Number:	88355874	NOVALERE
Serial Number:	88179843	OCTIQ
Serial Number:	88418893	OMEPRACARE DR
Serial Number:	87464856	PEVARX
Serial Number:	88232445	PINILTREX
Registration Number:	4122174	POLY-VI-FLOR
Serial Number:	87419117	PROSTAGORX
Serial Number:	74595092	PROSTASCINT
Serial Number:	88223453	RAYVA
Serial Number:	88230638	RAYVA
Serial Number:	87384668	RECALFOCUS
Serial Number:	88416815	REGOXIDINE
Serial Number:	88623032	REGOXIDINE
Serial Number:	88682675	SEMPRAE
Serial Number:	88591092	SEMPRAE LABORATORIES FROM SCIENCE TO SOL
Registration Number:	5899103	SEMPRAE LABORATORIES
Serial Number:	86361753	SENSUM+
Serial Number:	88877579	STEROXIN
Serial Number:	88957976	STEROXIN
Serial Number:	88228774	SUPPLEMENT HUNT
Serial Number:	88231719	SUPPLEMENT · HUNT S
Serial Number:	88625538	TESTO Aid
Serial Number:	87672904	THERMOMAX

Property Type	Number	Word Mark
Serial Number:	88179813	TREXAR
Serial Number:	88619785	TRPA COMPLEX
Serial Number:	87843417	URIVARX
Serial Number:	87321955	URIVARX
Serial Number:	87657969	URIVARX
Serial Number:	87843458	URIVARX UTI STRIPS
Serial Number:	88684157	VARICOLESS
Serial Number:	90244309	VASCAZEN
Serial Number:	85082477	VESELE
Serial Number:	87843540	VESELE
Serial Number:	87839918	VESELE
Serial Number:	87843565	VESELE NO STRIPS
Serial Number:	88373883	VITAROS
Serial Number:	88223461	VITAROS
Serial Number:	88230647	VITAROS
Serial Number:	87365716	XYRALID
Serial Number:	78884404	ZESTRA
Serial Number:	87882036	ZESTRA
Serial Number:	87626461	ZESTRA
Serial Number:	85284911	ZESTRA BLISS
Serial Number:	87601550	ZESTRA ESSENTIAL AROUSAL OILS
Serial Number:	87878279	ZESTRA ESSENTIAL TINGLING OILS
Serial Number:	85445196	ZESTRA GLIDE
Serial Number:	88013915	ZOLPIMIST
Serial Number:	88016434	ZOLPIMIST

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212.940.6562

**Email:** joanne.arnold@katten.com

**Correspondent Name:** Joanne BL Arnold

**Address Line 1:** Katten

**Address Line 2:** 575 Madison Avenue

**Address Line 4:** New York, NEW YORK 10022-2585

**NAME OF SUBMITTER:** Joanne BL Arnold

**SIGNATURE:** /Joanne BL Arnold/

**DATE SIGNED:** 03/22/2021

**Total Attachments: 25**

source=neos - intellectual property security agreement#page1.tif  
source=neos - intellectual property security agreement#page2.tif  
source=neos - intellectual property security agreement#page3.tif  
source=neos - intellectual property security agreement#page4.tif  
source=neos - intellectual property security agreement#page5.tif  
source=neos - intellectual property security agreement#page6.tif  
source=neos - intellectual property security agreement#page7.tif  
source=neos - intellectual property security agreement#page8.tif  
source=neos - intellectual property security agreement#page9.tif  
source=neos - intellectual property security agreement#page10.tif  
source=neos - intellectual property security agreement#page11.tif  
source=neos - intellectual property security agreement#page12.tif  
source=neos - intellectual property security agreement#page13.tif  
source=neos - intellectual property security agreement#page14.tif  
source=neos - intellectual property security agreement#page15.tif  
source=neos - intellectual property security agreement#page16.tif  
source=neos - intellectual property security agreement#page17.tif  
source=neos - intellectual property security agreement#page18.tif  
source=neos - intellectual property security agreement#page19.tif  
source=neos - intellectual property security agreement#page20.tif  
source=neos - intellectual property security agreement#page21.tif  
source=neos - intellectual property security agreement#page22.tif  
source=neos - intellectual property security agreement#page23.tif  
source=neos - intellectual property security agreement#page24.tif  
source=neos - intellectual property security agreement#page25.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Agreement”), dated as of March 19, 2021, is entered into by and among AYTU BIOSCIENCE, INC., a Delaware corporation, AYTU THERAPEUTICS, LLC, a Delaware limited liability company, INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, SEMPRAE LABORATORIES, INC., a Delaware corporation, NOVALERE, INC., a Delaware corporation, SUPPLEMENT HUNT, INC., a Nevada corporation, DELTA PRIME SAVINGS CLUB, INC., a Nevada corporation, AYTU CONSUMER HEALTH, INC a Delaware corporation (each of the foregoing, a “Grantor” and, collectively, the “Grantors”) and DEERFIELD MGMT, L.P., as collateral agent for Lenders (“Secured Party”).

### WITNESSETH:

WHEREAS, pursuant to that certain Facility Agreement (the “Facility Agreement”), dated as of May 11, 2016 (as amended by the First Amendment to Facility Agreement, dated as of June 1, 2017, the Second Amendment to Facility Agreement, dated as of November 5, 2018, the Third Amendment to Facility Agreement, dated as of March 26, 2019, the Fourth Amendment to Facility Agreement, dated as of October 2, 2019, the Fifth Amendment to Facility Agreement, dated as of May 6, 2020, and the Waiver, Consent and Sixth Amendment to Facility Agreement, dated as of March 19, 2021), between Neos Therapeutics, Inc., a Delaware corporation (the “Borrower”), and the lenders set forth on the signature pages of the Facility Agreement (the “Lenders”), the Lenders have made loans to the Borrower in accordance with the terms and conditions set forth therein;

WHEREAS, the Borrower and its Subsidiaries are parties to that Guaranty and Security Agreement, dated as of Mary 11, 2016 (as amended, restated supplemented or otherwise modified through the date hereof, the “Security Agreement”) among Borrower, its Subsidiaries, Secured Party and Lenders;

WHEREAS, pursuant to that certain Joinder to Guaranty and Security Agreement, dated as of March 19, 2021, Grantors have agreed to guarantee the Obligations under the Facility Agreement; and

WHEREAS, to secure their guaranty of the Obligations under the Facility Agreement, Grantors have agreed to enter into this Agreement;

NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in this Agreement, and for good and valuable consideration, the receipt of which is hereby acknowledged, the Grantor and Secured Party, hereby agree as follows:

#### SECTION 1. Definitions.

1.1 Generally. All references herein to the UCC shall mean the Uniform Commercial Code as in effect from time to time in the State of New York; provided, however, that if a term is defined in Article 9 of the UCC differently than in another Article thereof, the term shall have the meaning set forth in Article 9; provided further that, if by reason of mandatory provisions of law, perfection, or the effect of perfection or non-perfection, of the security interest in any IP Collateral or the availability of any remedy hereunder is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “UCC” means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such perfection or effect of perfection or non-perfection or availability of such remedy, as the case may be.

1.2 Definition of Certain Terms Used Herein. Unless the context otherwise requires, all capitalized terms used but not defined herein shall have the meanings set forth in the Facility Agreement.

4839-8176-53453

In addition, as used herein, the following terms shall have the following meanings:

“Copyrights” shall mean all United States copyrights and like protections in each work of authorship or derivative work thereof of Grantors, whether registered or unregistered and whether published or unpublished, including, without limitation, the copyright registrations listed on Exhibit A annexed hereto and made a part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

“Copyright Licenses” shall mean all agreements, whether written or oral, providing for the grant by or to any Grantor of any right under any Copyright.

“Copyright Office” shall mean the United States Copyright Office or any other federal governmental agency which may hereafter perform its functions.

“IP Collateral” shall have the meaning assigned to such term in Section 2 of this Agreement.

“Licenses” shall mean, collectively, the Copyright Licenses, Patent Licenses, Trademark Licenses, and any other license providing for the grant by or to any Grantor of any right under any Intellectual Property.

“Patents” shall mean all United States patents and applications for patents of Grantors and the inventions and improvements therein disclosed, and any and all divisions, revisions, reissues and continuations, continuations-in-part, extensions, and reexaminations of said patents including, without limitation, the patent registrations listed on Exhibit B annexed hereto and made a part hereof.

“Patent Licenses” shall mean all agreements, whether written or oral, providing for the grant by or to any Grantor of any right under any Patent.

“Permitted Liens” means Liens in favor of Secured Party.

“PTO” shall mean the United States Patent and Trademark Office or any other federal governmental agency which may hereafter perform its functions.

“Secured Obligations” shall mean the collective reference to (i) all Obligations of Grantors to Lenders, and (ii) all obligations of Grantors under the Security Agreement and this Agreement, respectively (including, without limitation, default interest accruing at the then applicable rate provided in the Facility Agreement and interest accruing at the then applicable rate after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to any Grantor, and post-filing or post-petition interest, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with, the Facility Agreement, or any other document executed and delivered in connection therewith, in each case whether on account of principal, interest, fees, indemnities, costs, expenses or otherwise (including, without limitation, all reasonable fees and disbursements of counsel to Secured Party that are required to be paid by Grantors pursuant to the terms of any of the foregoing agreements).

“Trademarks” shall mean all United States trademarks, trade names, corporate names, company names, domain names, business names, fictitious business names, trade dress, trade styles, service marks, designs, logos and other source or business identifiers of Grantors, whether registered or unregistered, including, without limitation, the trademark registrations listed on Exhibit C annexed hereto and made a

part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

“Trademark Licenses” shall mean all agreements, whether written or oral, providing for the grant by or to any Grantor of any right under any Trademark.

SECTION 2. Grant of Security Interest. As further security for the payment or performance, as the case may be, in full of the Secured Obligations, each Grantor hereby grants to Secured Party, for the benefit of the Lenders, a lien and continuing security interest, with a power of sale (which power of sale shall be exercisable only following the occurrence and during the continuance of an Event of Default), in all of the present and future right, title and interest of such Grantor in and to the following property, and each item thereof, whether now owned or existing or hereafter acquired or arising, together with all products, proceeds, substitutions, and accessions of or to any of the following property (collectively, the “IP Collateral”):

- (a) all Copyrights and Copyright Licenses;
- (b) all Patents and Patent Licenses;
- (c) all Trademarks and Trademark Licenses;
- (d) all other Licenses;
- (e) all renewals of any of the foregoing;
- (f) all of the following: all trade secrets, know-how and other proprietary information; works of authorship and other copyright works (including copyrights for computer programs), and all tangible and intangible property embodying the foregoing; inventions (whether or not patentable) and all improvements thereto; industrial design applications and registered industrial designs; books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases, and other physical manifestations, embodiments or incorporations of any of the foregoing, and any Licenses in any of the foregoing, and all other Intellectual Property and proprietary rights;
- (g) all General Intangibles connected with the use of, or related to, any and all of the foregoing (including, without limitation, all goodwill of such Grantor and its business, products and services appurtenant to, associated with, or symbolized by, any Intellectual Property and the use thereof);
- (h) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect to any of the foregoing, including, without limitation, payments under all Licenses entered into in connection therewith and damages and payments for past or future infringements, misappropriations or dilutions thereof;
- (i) the right to sue for past, present and future infringements, misappropriations, and dilutions of any of the foregoing; and
- (j) all of such Grantor’s rights corresponding to any of the foregoing throughout the world.



Notwithstanding anything herein, or in any other Loan Document, to the contrary, in no event shall the IP Collateral include any Excluded Property.

SECTION 3. Grantors' Representations and Warranties. In addition to any representations and warranties contained in the Security Agreement, the Grantors represent and warrant that:

(a) Exhibit A is a true, correct and complete list of all United States registered Copyrights owned by Grantors as of the date hereof.

(b) Exhibit B is a true, correct and complete list of all registered United States Patents owned by Grantors as of the date hereof.

(c) Exhibit C is a true, correct and complete list of all United States registered Trademarks owned by Grantors as of the date hereof.

SECTION 4. Agreement Applies to Future Intellectual Property.

(a) The provisions of this Agreement shall automatically apply to any such additional Intellectual Property acquired after the date of this agreement, above, all of which shall be deemed to be and treated as IP Collateral within the meaning of this Agreement. Upon the acquisition by any Grantor of any additional material Intellectual Property and the reasonable request of Secured Party, such Grantor shall promptly deliver to Secured Party an updated Exhibit A, B, and/or C (as applicable) to this Agreement and hereby authorizes the Secured Party to file, at such Grantor's expense, such updated Exhibit as set forth in Section 5(b).

(b) Each Grantor shall execute and deliver, and shall record, any and all agreements, instruments, documents and papers as the Secured Party may reasonably request to evidence Secured Party's security interest in any material IP Collateral (including, without limitation, filings with the PTO, the Copyright Office or any similar office), and each Grantor hereby appoints Secured Party as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all such acts of such attorney being hereby ratified and confirmed; provided, however, that Secured Party's taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

SECTION 5. Grantors' Rights To Enforce Intellectual Property. So long as no Event of Default has occurred and is continuing, the Grantors shall have the exclusive right to sue for past, present and future infringement of the IP Collateral, including the right to seek injunctions and/or money damages in an effort by the Grantors to protect the IP Collateral against encroachment by third parties; provided, however, that:

(a) any money damages awarded or received by any Grantor on account of such suit (or the threat of such suit) shall constitute IP Collateral; and

(b) upon the occurrence and during the continuance of any Event of Default, the Secured Party, by notice to the Grantors, may terminate or limit the Grantors' rights under this Section 5.

SECTION 6. Grantors' Rights to License Intellectual Property. Secured Party agrees that all rights of any licensee of the IP Collateral shall survive any exercise of rights and remedies by Secured Party in connection with this Agreement, including any foreclosure and subsequent transfer of such IP Collateral

by Secured Party. Secured Party further agrees, following the reasonable request of any Grantor or any licensee of the IP Collateral and at such Grantor's or such licensee's expense, to execute such documents and to take such actions as may be reasonably requested by such Grantor or such licensee to preserve and protect the rights of any such licensee.

SECTION 7. Secured Party's Actions To Protect Intellectual Property. Upon the occurrence and during the continuance of any Event of Default, Secured Party, acting in its own name or in that of any Grantor, may (but shall not be required to) act in such Grantor's place and stead and/or in Secured Party's own right in connection therewith.

SECTION 8. Rights Upon Default. Upon the occurrence and during the continuance of an Event of Default, in addition to all other rights and remedies, Secured Party may exercise all rights and remedies of a secured party under the Uniform Commercial Code as adopted in the State of New York, with respect to the IP Collateral, in addition to which Secured Party may sell, license, assign, transfer, or otherwise dispose of the IP Collateral, subject to those restrictions to which Grantors are subject under applicable law and by contract. Any Person may conclusively rely upon an affidavit of an officer of Secured Party that an Event of Default has occurred and that Secured Party is authorized to exercise such rights and remedies.

SECTION 9. Secured Party as Attorney-In-Fact.

(a) Each Grantor hereby irrevocably makes, constitutes and appoints Secured Party (and all officers, employees or agents designated by Secured Party) as and for such Grantor's true and lawful agent and attorney-in-fact, and in such capacity Secured Party shall have the right, with power of substitution for such Grantor and in such Grantor's name or otherwise, for the use and benefit of Secured Party:

(i) to supplement and amend from time to time Exhibits A, B and C of this Agreement to include any newly developed, applied for, registered, or acquired United States Intellectual Property of such Grantor and any intent-to-use Trademark applications for which a statement of use or an amendment to allege use has been filed and accepted by the PTO;

(ii) following the occurrence and during the continuance of any Event of Default, to exercise any of the rights and powers referenced herein; and

(iii) following the occurrence and during the continuance of any Event of Default, to execute all such instruments, documents, and papers as the Secured Party reasonably determines to be necessary or desirable in connection with the exercise of such rights and remedies and to cause the sale, license, assignment, transfer, or other disposition of the IP Collateral, subject to those restrictions to which such Grantor is subject under applicable law and by contract.

(b) The power of attorney granted herein, being coupled with an interest, shall be irrevocable until the Security Agreement is terminated.

(c) Secured Party shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 9(a), but if Secured Party elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such

exercise of power, and shall not be responsible to any Grantor for any act or omission to act, except where a court of competent jurisdiction determines by final and non-appealable judgment that the subject act or omission to act has resulted from the gross negligence or willful misconduct of Secured Party.

SECTION 10. Secured Party's Rights. Any use by Secured Party of the IP Collateral, as authorized hereunder in connection with the exercise of Secured Party's rights and remedies under this Agreement shall be without any liability for royalties or other related charges.


SECTION 11. Further Assurances. Each Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further documents, financing statements, agreements and instruments and take all such further actions as Secured Party may from time to time reasonably request to better assure, preserve, protect and perfect the security interest in the IP Collateral granted pursuant to this Agreement and the rights and remedies created hereby or the validity or priority of such security interest including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the security interest and the filing of any financing statements or other documents in connection herewith or therewith.

SECTION 12. Choice of Laws. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.


**[SIGNATURE PAGE FOLLOWS]**

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement under seal as of the day and year first above written.


**AYTU BIOSCIENCE, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer


**AYTU THERAPEUTICS LLC**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer


**INNOVUS PHARMACEUTICALS, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer


**SEMPRAE LABORATORIES, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer


**NOVALERE, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer


**SUPPLEMENT HUNT, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer

**DELTA PRIME SAVINGS CLUB, INC.**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer

**AYTU CONSUMER HEALTH, INC**

By:   
Name: Joshua Disbrow  
Title: President and Chief Executive Officer

COLLATERAL AGENT:

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: 

Name: David J. Clark

Title: Authorized Signatory

EXHIBIT A  
List of Copyrights

**Copyright Registrations**

<b>Loan Party Obligor</b>	<b>Copyright Title</b>	<b>Issue Date</b>	<b>Copyright Number</b>	<b>Expiration Date</b>
Innovus Pharmaceuticals, Inc.	Sensum+ Clinical Studies	1/2/2019	TX 8-672-337	1/2/2114

**EXHIBIT B**List of Patents**Patent Registrations**

<b>Loan Party Obligor</b>	<b>Patent Registration Number</b>	<b>Registration Date</b>	<b>Patent Application Number</b>	<b>Application Date</b>
<b>Innovus Pharmaceuticals</b>			17/136,932	December 29, 2020
<b>Innovus Pharmaceuticals</b>	9821021	11/21/2017	15/496,861 (US)	4/25/2012
<b>Innovus Pharmaceuticals</b>	9833488	12/5/2017	14395919 (US)	3/15/2013
<b>Innovus Pharmaceuticals</b>			PCT/US 2013/032371	3/15/2013
<b>Innovus Pharmaceuticals</b>	2,910,103	7/21/2020	CA2910103 (Canada)	3/15/2013
<b>Innovus Pharmaceuticals</b>	ZL201380033442X		2013380033442 (China)	3/15/2013
<b>Innovus Pharmaceuticals</b>	2844219		2844219 (EU)	11/24/2014
<b>Innovus Pharmaceuticals</b>	235339	7/31/2018	235339 (Israel)	10/26/2014
<b>Innovus Pharmaceuticals</b>	353088	12/19/2018	MX/a/2014/012925 (Mexico)	10/24/2014



<b>Innovus Pharmaceuticals</b>	37459	9/8/1937	37459 (Morocco)	3/15/2013
<b>Innovus Pharmaceuticals</b>	10-2074013	1/30/2020	10-2014-7033142 (South Korea)	11/25/2014
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041141	6/27/2001
<b>Innovus Pharmaceuticals</b>	2417552	5/13/2014	PCT/US2001/041141 (Canada)	6/27/2001
<b>Innovus Pharmaceuticals</b>	EP1328281	8/15/2007	PCT/US2001/041141 (France)	6/27/2001
<b>Innovus Pharmaceuticals</b>	EP1328281	8/15/2007	PCT/US2001/041142 (Germany)	6/27/2001
<b>Innovus Pharmaceuticals</b>	EP1328281	8/15/2007	PCT/US2001/041143 (Italy)	6/27/2001
<b>Innovus Pharmaceuticals</b>	EP1328281	8/15/2007	PCT/US2001/041144 (U.K.)	6/27/2001
<b>Innovus Pharmaceuticals</b>	ES2291333	8/15/2007	PCT/US2001/041145 (Spain)	6/27/2001
<b>Innovus Pharmaceuticals</b>	7875299	1/25/2011	PCT/US2001/041146	4/29/2004
<b>Innovus Pharmaceuticals</b>	8128972	3/6/2012	PCT/US2001/041147	1/20/2011
<b>Innovus Pharmaceuticals</b>	10,456,401	10/29/2019	PCT/US2001/041148	5/14/2018
<b>Innovus Pharmaceuticals</b>	10,864,205	12/15/2020	PCT/US2001/041149	12/1/2017
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041150	9/24/2019
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041151	5/14/2018

			(PCT)	
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041152	5/14/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041153	11/30/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041154	5/14/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041155	12/1/2017
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041156	12/1/2017
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041157	11/30/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041158	8/4/2020
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041159	12/1/2017
<b>Innovus Pharmaceuticals</b>	10,500,199 B2	12/10/2019	PCT/US2001/041160	12/1/2017
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041161	11/8/2019
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041162	11/30/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041163	3/7/2017
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041164	12/14/2017

<b>Innovus Pharmaceuticals</b>			PCT/US2001/041165	
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041166	8/14/2019
<b>Innovus Pharmaceuticals</b>			PCT/US2001/041167 (PCT)	2/7/2019
<b>Innovus Pharmaceuticals</b>				11/30/2018
<b>Innovus Pharmaceuticals</b>			3,026,026 (Canada)	11/30/2018
<b>Innovus Pharmaceuticals</b>			PCT/US2018/062440 (PCT)	11/26/2018
<b>Innovus Pharmaceuticals</b>			16/762,261	5/7/2020
<b>Innovus Pharmaceuticals</b>			3083274 (Canada)	6/18/2020
<b>Innovus Pharmaceuticals</b>			16/842,228	4/7/2020
<b>Innovus Pharmaceuticals</b>			3084207 (Canada)	4/7/2020

<b>Innovus Pharmaceuticals</b>			62/982,725	2/27/2020
<b>Innovus Pharmaceuticals</b>			PCT/US2020/027083 (PCT)	4/7/2020
<b>Innovus Pharmaceuticals</b>			16/740,194	1/10/2020
<b>Innovus Pharmaceuticals</b>			PCT/US2020/0131146 (PCT)	1/10/2020

## EXHIBIT C

### List of Trademarks

#### **Trademark Registrations**

<b>Owner</b>	<b>Mark Name</b>	<b>Jurisdiction</b>	<b>Type of Mark</b>	<b>Serial Number</b>	<b>Application Date</b>	<b>Registration Date</b>	<b>Registration Number</b>
Innovus	ACC NEURITE COMPLEX™	U.S.	Word Mark	88631225	9/25/2019		
Innovus	ACC NEURITE COMPLEX™	Canada	Word Mark	1986764	9/25/2019		
Innovus	ALLERVARX®	U.S.	Word Mark	87321960	4/25/2017	10/31/2017	5325766
Innovus	ALLERVARX™	Canada	Word Mark	1962771	5/14/2019		
Innovus	APEAZ ®	U.S.	Word Mark	87365742	3/9/2017	9/26/2017	5296449
Innovus	APEAZ ®	Canada	Word Mark	1878006	1/17/2018	11/8/2019	1062484
Innovus	ARTHRIVARX™	Canada	Word Mark	1966576	6/3/2019		
Innovus	ARTHRIVARX®	U.S.	Word Mark	87497489	6/20/2017	2/13/2018	5403502
Aytu Bioscience	AYTU®	U.S.	Word Mark	86724493	8/13/2015	4/11/2017	5182394
Aytu Bioscience	AYTU®	Australia	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Aytu Bioscience	AYTU®	Canada	Word Mark	1764169	1/20/2016	12/21/2018	1011776
Aytu Bioscience	AYTU®	European Union	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Aytu Bioscience	AYTU®	Israel	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Aytu Bioscience	AYTU®	Japan	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Aytu Bioscience	AYTU®	South Korea	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Aytu Bioscience	AYTU®	WIPO	Word Mark	1291669	1/21/2016	1/21/2016	1291669
Innovus	AYTUMUNE™	U.S.	Word Mark	90160190	9/4/2020		
Innovus	AYTUMUNE™	U.S.	Design Mark	90160351	9/4/2020		
Innovus	AYTUMUNE™	Canada	Word Mark	2049982	9/4/2020		
Innovus	AYTUMUNE™	Canada	Design Mark	2049997	9/4/2020		
Aytu Bioscience	AYTUVIR™	U.S.	Word Mark	88843582	3/22/2020		
Aytu Bioscience	AYTUVIR™	U.S.	Word Mark	88843583	3/22/2020		
Aytu Bioscience	AYTUVIR™	U.S.	Word Mark	88843587	3/22/2020		
Innovus	AYTU CONSUMER HEALTH™	U.S.	Word Mark	90132694	8/24/2020		
Innovus	BEYOND HUMAN®	U.S.	Word Mark	85967626	6/24/2013	8/26/2014	4591320
Innovus	BEYOND HUMAN®	U.S.	Word Mark	87605268	9/12/2017	7/24/2018	5522808
Innovus	BEYOND HUMAN®	U.S.	Design Mark	88356845	3/26/2019	9/3/2019	5851637
Innovus	BHT®	U.S.	Word Mark	88378275	4/9/2019	10/1/2019	5874344
Innovus	BHT™	Canada	Word Mark	1956404	4/9/2019		

Innovus	<b>BOSTON TOPICALS®</b>	U.S.	Word Mark	88178462	11/1/2018	12/31/2019	5947488
Innovus	<b>BOSTON TOPICALS™</b>	Canada	Word Mark	1928562	11/2/2018		
Innovus	<b>BREASTLIFT™</b>	Canada	Word Mark	1936283	12/14/2018		
Innovus	<b>BREASTLIFT™</b>	Canada	Design Mark	1936278	12/14/2018		
Innovus	<b>BREASTLIFT®</b>	U.S.	Word Mark	88230627	12/14/2018	11/19/2019	5912470
Innovus	<b>BREASTLIFT®</b>	U.S.	Design Mark	88230629	12/14/2018	11/19/2019	5912471
Innovus	<b>CARDIOTEK®</b>	U.S.	Word Mark	75469228	4/16/1998	1/22/2002	2532414
Innovus	<b>CARVANUM®</b>	U.S.	Word Mark	88040646	7/17/2018	5/28/2019	5765579
Innovus	<b>CARVANUM®</b>	European Union	Word Mark	A0086505	6/3/2019	6/3/2019	1475674
Innovus	<b>CARVANUM™</b>	Canada	Word Mark	1909852	7/17/2018		
Aytu Bioscience	<b>CECLOR™</b>	U.S.	Word Mark	86041180	8/19/2013		
Innovus	<b>DELTA PRIME SAVINGS CLUB™</b>	Canada	Word Mark	1958028	4/17/2019		
Innovus	<b>DELTA PRIME SAVINGS CLUB®</b>	U.S.	Word Mark	88381293	4/11/2019	10/22/2019	5893300
Innovus	<b>DELTA PRIME SAVINGS CLUB®</b>	European Union	Word Mark	A0085745	5/6/2019	5/6/2019	1471174
Innovus	<b>DHTCARE®</b>	European Union	Word Mark	A0086175	5/20/2019	5/20/2019	1474098
Innovus	<b>DHTCARE™</b>	U.S.	Word Mark	88429943	5/14/2019		
Innovus	<b>DHTCARE™</b>	Canada	Word Mark	1962927	5/14/2019		
Innovus	<b>DIABASENS®</b>	U.S.	Word Mark	87717770	12/12/2017	10/16/2018	5588013
Innovus	<b>DIABASENS®</b>	Mexico	Combined	2212843	5/28/2019	10/7/2020	2153518
Innovus	<b>DIABASENS®</b>	Mexico	Combined	2212842	5/28/2019	10/2/2020	2152087
Innovus	<b>DIABASENS™</b>	U.S.	Design Mark	88838768	3/18/2020		
Innovus	<b>DIABASENS™</b>	Canada	Word Mark	1955441	4/4/2019		
Innovus	<b>DIGERYXN®</b>	U.S.	Word Mark	88877573	4/18/2020	3/2/2021	6284751
Innovus	<b>DIGERYXN™</b>	U.S.	Design Mark	88957866	6/10/2020		
Innovus	<b>DIGERYXN™</b>	Canada	Word Mark	2025127	4/29/2020		
Innovus	<b>EJECTDELAY®</b>	U.S.	Word Mark	85914704	4/25/2013	8/26/2014	4593829
Innovus	<b>EJECTDELAY®</b>	Morocco	Word Mark	A0037420 1175561	4/25/2013	8/7/2014	1175561
Innovus	<b>EJECTDELAY®</b>	Colombia	Word Mark	A0037420 1175561	4/25/2013	3/26/2015	1175561
Semprae	<b>EJECTDELAY®</b>	Peru	Word Mark	724829	10/19/2017	2/14/2018	258932
Innovus	<b>EJECTDELAY®</b>	Vietnam	Word Mark	A0037420 1175561	8/12/2013	10/9/2014	1175561
Innovus	<b>EURYCO-8™</b>	U.S.	Word Mark	88359960	3/27/2019		
Innovus	<b>EURYCO-8™</b>	Canada	Word Mark	1954673	4/1/2019		
Innovus	<b>EURYCO-10™</b>	U.S.	Word Mark	88658569	10/17/2019		

Innovus	EURYCO-10™	U.S.	Design Mark	88830315	3/11/2020		
Innovus	EURYCO-10™	Canada	Word Mark	1990923	10/17/2019		
Innovus	EURYCO-10®	E.U.	Word Mark	A0090867	10/22/2019	10/22/2019	1504545
Innovus	EURYCO-10®	Japan	Word Mark	A0090867	10/22/2019	10/22/2019	1504545
Innovus	EURYCO-10®	Indonesia	Word Mark	A0090867	10/22/2019	10/22/2019	1504545
Innovus	EURYCO-10®	China	Word Mark	A0090867	10/22/2019	10/22/2019	1504545
Innovus	EURYCO-10™	China	Word Mark	46481787	5/20/2020		
Semprae	FLEXILON™	U.S.	Word Mark	88746003	1/3/2020		
Semprae	FLEXILON™	Canada	Word Mark	1928569	11/5/2018		
Semprae	FLOVINTRO®	U.S.	Word Mark	88179840	11/2/2018	8/6/2019	5830310
Semprae	FLOVINTRO™	Canada	Word Mark	1928575	11/5/2018		
Innovus	FLUTICANEX™	U.S.	Word Mark	87671266	11/3/2017		
Innovus	FLUTICANX™	U.S.	Word Mark	87671340	11/3/2017		
Innovus	FLUTICARE®	U.S.	Word Mark	87262502	12/8/2016	11/7/2017	5331309
Innovus	FLUTICARE®	U.S.	Design Mark	87601188	9/8/2017	5/15/2018	5471512
Innovus	FLUTICARE™	Canada	Word Mark	1966737	6/4/2019		
Innovus	FLUTICARE™	Canada	Design Mark	1966744	6/4/2019		
Innovus	FORTEBEE™	U.S.	Word Mark	90485739	1/25/2021		
Innovus	FORTEBEE™	Canada	Word Mark	2079637	1/25/2021		
Semprae	FROM SCIENCE TO SOLUTION®	U.S.	Word Mark (Slogan)	88591106	8/23/2019	3/17/2020	6013513
Semprae	FROM SCIENCE TO SOLUTION™	Canada	Word Mark (Slogan)	1982047	8/23/2019		
Innovus	GLUCOGORX™	U.S.	Word Mark	87617672	9/21/2017		
Innovus	GLUCOGORX®	U.S.	Design Mark	88838817	3/18/2020	9/22/2020	6158211
Innovus	GLUCOGORX®	U.S.	Word Mark	88065228	8/3/2018	3/5/2019	5691708
Aytu Bioscience	HEALIGHT®	WIPO	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Aytu Bioscience	HEALIGHT™	U.S.	Word Mark	88885353	4/23/2020		
Aytu Bioscience	HEALIGHT™	Canada	Word Mark	2025025	4/28/2020		
Aytu Bioscience	HEALIGHT®	E.U.	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Aytu Bioscience	HEALIGHT®	China	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Aytu Bioscience	HEALIGHT®	Japan	Word Mark	A0096260	4/28/2020	4/28/2020	1536778

Aytu Bioscience	HEALIGHT®	South Korea	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Aytu Bioscience	HEALIGHT®	Brazil	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Aytu Bioscience	HEALIGHT®	India	Word Mark	A0096260	4/28/2020	4/28/2020	1536778
Innovus	HEALTHIFEET®	U.S.	Word Mark	77346838	12/7/2007	9/16/2008	3502924
Innovus	HEALTHIFEET®	Canada	Word Mark	1398607	6/9/2018	12/3/2009	TMA754527
Innovus	ICARESUP®	U.S.	Word Mark	88498145	7/2/2019	12/24/2019	5944190
Innovus	ICARESUP®	Singapore	Combined Mark	40201917111V	8/7/2019	8/7/2019	40201917111V
Innovus	ICARESUP®	Japan	Combined Mark	2019-110790	8/19/2019	7/14/2020	6269495
Innovus	ICARESUP®	China	Combined Mark	40176705	8/6/2019	7/13/2020	40176705
Innovus	ICARESUP™	Canada	Word Mark	1974362	7/8/2019		
Innovus	INNOVSUM™	South Korea	Word Mark	40-2019-018322	11/27/2019		
Innovus	INNOVUS PHARMA ®	U.S.	Word Mark	85412980	9/1/2011	12/24/2013	4455489
Innovus	INNOVUS PHARMA ®	U.S.	Design Mark	87794483	2/12/2018	9/27/2018	5572238
Innovus	INNOVUS PHARMA ®	European Union	Combined	17939285	8/3/2018	8/3/2018	17939285
Innovus	INNOVUS PHARMA ®	U.S.	Word Mark	88331577	3/8/2019	9/10/2019	5857357
Innovus	INNOVUS PHARMA ®	U.S.	Word Mark	88466887	6/10/2019	12/24/2019	5943825
Innovus	INNOVUS PHARMA ®	U.S.	Word Mark	88597743	8/29/2019	3/31/2020	6023081
Innovus	INNOVUS PHARMA™	Canada	Word Mark	1968428	6/10/2019		
Innovus	INNOVUS PHARMA ®	Canada	Word Mark	1913085	8/2/2018	2/22/2021	1094157
Innovus	INNOVUS PHARMA ®	Canada	Design Mark	1913084	8/2/2018	2/22/2021	1094156
Sempraec	IRACILXL®	U.S.	Word Mark	88179847	11/2/2018	10/29/2019	5898789
Sempraec	IRACIL XL™	Canada	Word Mark	1928578	11/5/2018		
Innovus	KETOGORX™	U.S.	Word Mark	88826450	3/9/2020		
Innovus	KETOGORX™	U.S.	Design Mark	88826515	3/9/2020		
Innovus	KETOGORX™	Canada	Word Mark	2016336	3/9/2020		
Innovus	KETOGORX™	Canada	Design Mark	2016335	3/9/2020		
Innovus	M.A.C. DEFENSE™	U.S.	Word Mark	90524780	2/11/2021		
Innovus	M.A.C. DEFENSE™	Canada	Word Mark	2084318	2/11/2021		
Aytu Therapeutics	MATERNA®	U.S.	Word Mark	85365008	7/7/2011	7/5/2016	4993604
Aytu Bioscience	MIOXSYS®	U.S.	Word Mark	86724491	8/13/2015	2/7/2017	5138342



Aytu Bioscience	MIOXSYS®	Australia	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Aytu Bioscience	MIOXSYS®	Canada	Word Mark	1764170	1/20/2016	12/21/2018	1011775
Aytu Bioscience	MIOXSYS®	European Union	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Aytu Bioscience	MIOXSYS®	Israel	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Aytu Bioscience	MIOXSYS®	Japan	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Aytu Bioscience	MIOXSYS®	South Korea	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Aytu Bioscience	MIOXSYS®	WIPO	Word Mark	1290107	1/21/2016	1/21/2016	1290107
Innovus	MUSCLIN®	U.S.	Word Mark	87527180	7/13/2017	10/23/2018	5591316
Innovus	MUSCLIN®	U.S.	Design Mark	88057974	7/30/2018	3/26/2019	5709304
Innovus	MUSCLIN®	Canada	Word Mark	1910468	7/19/2018	2/17/2021	1093886
Innovus	MUSCLIN®	Canada	Design Mark	1912350	7/30/2018	2/17/2021	1093887
Innovus	MZS®	U.S.	Word Mark	88228922	12/13/2018	10/29/2019	5894715
Innovus	MZS MELATONIN™	U.S.	Word Mark	87820415	3/5/2018		
Innovus	MZS SLEEPING AID™	U.S.	Word Mark	88506510	7/9/2019		
Innovus	MZS SLEEPING AID®	U.S.	Word Mark	87820758	3/6/2018	5/28/2019	5764852
Innovus	NASOVA™	U.S.	Word Mark	87684151	11/14/2017		
Semprae	NEURITERX®	U.S.	Word Mark	87957369	6/11/2018	5/21/2019	5759199
Semprae	NEURITERX®	Canada	Word Mark	1903719	6/11/2018	10/7/2020	TMA1083838
Novalere	NOVALERE ®	U.S.	Word Mark	86224631	3/18/2014	10/14/2014	4620829
Novalere	NOVALERE ®	U.S.	Design Mark	88355874	3/25/2019	10/15/2019	5883646
Innovus	OCTIQ™	Canada	Word Mark	1928581	11/5/2018		
Innovus	OCTIQ™	U.S.	Word Mark	88179843	11/2/2018		
Innovus	OMEPRACARE DR®	U.S.	Word Mark	88418893	5/7/2019	5/26/2020	6065617
Innovus	OMEPRACARE DR™	Canada	Word Mark	1961426	5/7/2019		
Innovus	OMEPRACARE DR®	European Union	Word Mark	A0085919	5/13/2019	5/13/2019	1473016
Innovus	PEVARX®	U.S.	Word Mark	87464856	5/25/2017	2/13/2018	87464856
Semprae	PINILTREX®	U.S.	Word Mark	88232445	12/17/2018	8/20/2019	5841292
Innovus	PINILTREX®	South Korea	Combined Mark	40-2019-0178340	11/19/2019	11/19/2020	40-1663950
Semprae	PINILTREX™	Canada	Word Mark	1936696	12/18/2018		

Aytu Therapeutics	POLY-VI-FLOR®	U.S.	Word Mark	777848331	7/20/2009	4/3/2012	4122174
Innovus	PROSTAGORX®	U.S.	Word Mark	87419117	4/20/2017	10/31/2017	5325876
Innovus	PROSTAGORX®	Algeria	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Bahrain	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Egypt	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Iran	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Morocco	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Oman	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Syria	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Tunisia	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	Turkey	Word Mark	A0073484	2/9/2018	2/9/2018	1426637
Innovus	PROSTAGORX®	China	Chinese Characters	27554439	11/17/2017	10/21/2018	27554439
Innovus	PROSTAGORX®	China	Word Mark	24314977	5/24/2017	5/28/2018	24314977
Innovus	PROSTAGORX®	European Union	Word Mark	13016	8/23/2018	8/21/2018	1428555
Innovus	PROSTAGORX®	UAE	Word Mark	295382	7/15/2018	7/15/2018	295382
Innovus	PROSTAGORX®	Canada	Word Mark	1876844	1/10/2018	10/16/2019	1059118
Aytu Bioscience	PROTASCINT®	U.S.	Word Mark	74595092	11/4/1994	3/25/1997	2048135
Innovus	RAYVA®	U.S.	Word Mark	88223453	12/10/2018	1/21/2020	5968807
Innovus	RAYVA®	U.S.	Design Mark	88230638	12/14/2018	1/21/2020	5968839
Innovus	RAYVA®	European Union	Word Mark	A0081566	12/10/2018	12/10/2018	1447642
Innovus	RAYVA™	Canada	Word Mark	1935131	12/10/2018		
Innovus	RECALFOCUS®	U.S.	Word Mark	87384668	3/25/2017	11/14/2017	5337245
Innovus	RECALFOCUS™	Canada	Word Mark	1976106	7/17/2019		
Innovus	RECALMAX®	Mexico	Word Mark	2066302	6/25/2018	6/25/2018	1926675
Innovus	REGOXIDINE®	U.S.	Word Mark	88416815	5/6/2019	1/7/2020	5957832
Innovus	REGOXIDINE®	U.S.	Design Mark	88623032	9/19/2019	5/12/2020	6055145
Innovus	REGOXIDINE™	Canada	Word Mark	1961103	5/6/2019		
Innovus	REGOXIDINE®	European Union	Word Mark	A0085744	5/6/2019	5/6/2019	1474652
Semprae	SEMPRAE®	U.S.	Design Mark	88682675	11/6/2019	3/24/2020	6019061
Semprae	SEMPRAE LABORATORIES®	U.S.	Design Mark	88591092	8/23/2019	3/24/2020	6018062
Semprae	SEMPRAE LABORATORIES®	U.S.	Word Mark	88179847	2/22/2019	10/29/2019	5899103
Innovus	SEMPRAE LABORATORIES®	European Union	Word Mark	A0083931	3/6/2019	3/6/2019	1460862

Semprae	<b>SEMPRAE LABORATORIES™</b>	Canada	Design Mark	1982049	8/23/2019		
Semprae	<b>SEMPRAE LABORATORIES™</b>	Canada	Word Mark	1949866	3/6/2019		
Innovus	<b>SENSUM+®</b>	European Union	Word Mark	12992	8/23/2018	8/21/2018	1430876
Innovus	<b>SENSUM+®</b>	Peru	Word Mark	724830	10/19/2017	5/24/2018	267294
Innovus	<b>SENSUM+®</b>	Peru	Word Mark	724832	10/19/2017	9/17/2025	265062
Innovus	<b>SENSUM+®</b>	U.S.	Word Mark	86361753	8/8/2014	8/11/2015	4788787
Innovus	<b>SENSUM+®</b>	India	Word Mark	A0097245	6/5/2020	6/5/2020	1542041
Innovus	<b>SENSUM+®</b>	Mexico	Word Mark	1484809	7/2/2019	7/2/2019	1484809
Innovus	<b>SENSUM+®</b>	Japan	Word Mark	A0087346	7/2/2019	7/2/2019	1484809
Innovus	<b>SENSUM+™</b>	Canada	Word Mark	1973557	7/2/2019		
Innovus	<b>STEROXIN™</b>	U.S.	Word Mark	88877579	4/18/2020	3/2/2021	6284752
Innovus	<b>STEROXIN®</b>	U.S.	Design Mark	88957976	6/10/2020		
Innovus	<b>STEROXIN™</b>	Canada	Word Mark	2025126	4/29/2020		
Innovus	<b>SUPPLEMENT HUNT®</b>	U.S.	Word Mark	88228774	12/13/2018	7/23/2019	5812156
Innovus	<b>SUPPLEMENT HUNT®</b>	U.S.	Design Mark	88231719	12/17/2018	7/30/2019	5819664
Innovus	<b>SUPPLEMENT HUNT™</b>	Canada	Word Mark	1935969	12/13/2018		
Innovus	<b>SUPPLEMENT HUNT™</b>	Canada	Design Mark	1936420	12/17/2018		
Innovus	<b>TESTOAID™</b>	U.S.	Word Mark	88625538	9/20/2019		
Innovus	<b>TESTOAID™</b>	Canada	Word Mark	1986229	9/20/2019		
Innovus	<b>THERMOMAX®</b>	U.S.	Word Mark	87672904	11/6/2017	6/12/2018	5491702
Innovus	<b>THERMOMAX®</b>	Canada	Word Mark	1897467	5/4/2018	2/21/2020	1897467
Innovus	<b>TREXAR®</b>	U.S.	Word Mark	88179813	11/2/2018	7/23/2019	5815306
Innovus	<b>TREXAR™</b>	Canada	Word Mark	1928584	11/5/2018		
Innovus	<b>TRPA COMPLEX™</b>	U.S.	Word Mark	88619785	9/17/2019		
Innovus	<b>URIVARX®</b>	Canada	Design Mark	1889372	3/21/2018	12/26/2019	TMA1067387
Innovus	<b>URIVARX®</b>	Canada	Word Mark	1889757	3/23/2018	12/26/2019	TMA1067388
Innovus	<b>URIVARX®</b>	U.S.	Design Mark	87843417	3/21/2018	12/4/2018	5624250
Innovus	<b>URIVARX®</b>	U.S.	Word Mark	87321955	2/2/2017	10/31/2017	5325765
Innovus	<b>URIVARX®</b>	U.S.	Word Mark	87657969	10/24/2017	8/21/2018	5547457
Innovus	<b>URIVARX®</b>	Canada	Word Mark	1870931	12/1/2017	9/23/2019	1055899
Innovus	<b>URIVARX UTI STRIPS®</b>	U.S.	Design Mark	87843458	3/21/2018	1/1/2019	5645364
Innovus	<b>URIVARX UTI STRIPS®</b>	Canada	Design Mark	1889380	3/21/2018	7/22/2019	1043688

Innovus	VARICOLESS®	U.S.	Word Mark	88684157	11/7/2019	2/16/2021	6273812
Innovus	VARICOLESS™	Canada	Word Mark	1994853	11/7/2019		
Aytu Bioscience	VASCAZEN™	U.S.	Word Mark	90244309	10/9/2020		
Aytu Bioscience	VASCAZEN™	Canada	Word Mark	2056846	10/9/2020		
Innovus	VESELE ®	U.S.	Word Mark	85082477	7/12/2010	9/25/2012	4214489
Innovus	VESELE ®	U.S.	Design Mark	87843540	3/21/2018	11/6/2018	5600662
Innovus	VESELE ®	European Union	Word Mark	13310	3/21/2018	8/21/2018	1456105
Innovus	VESELE ®	U.S.	Word Mark	87839918	3/19/2018	1/1/2019	5645355
Innovus	VESELE ®	Canada	Design Mark	1889358	3/21/2018	9/23/2019	1055902
Innovus	VESELE ®	Canada	Word Mark	1889759	3/23/2018	7/4/2019	1036196
Innovus	VESELE ®	Canada	Word Mark	1870925	12/1/2017	12/2/2019	TMA1064960
Innovus	VESELE NO STRIPS®	Canada	Design Mark	1889365	3/21/2018	8/14/2019	1048973
Innovus	VESELE NO STRIPS®	U.S.	Design Mark	87843565	3/21/2018	1/19/2019	5645366
Innovus	VITAROS™	U.S.	Word Mark	88373883	4/5/2019		
Innovus	VITAROS™	U.S.	Word Mark	88223461	12/10/2018		
Innovus	VITAROS™	U.S.	Design Mark	88230647	12/14/2018		
Innovus	VITAROS™	Canada	Word Mark	1935130	12/10/2018		
Innovus	XYRALID®	Canada	Word Mark	1876838	1/10/2018	3/12/2020	1074982
Innovus	XYRALID®	U.S.	Word Mark	87365716	3/9/2017	2/6/2018	5397912
Semprae	ZASEMA®	South Korea	Word Mark	40-2017-0165235	12/22/2017	8/9/2018	40-1386297
Semprae	ZESTRA®	U.S.	Word Mark	78884404	5/16/2006	3/27/2007	3222491
Semprae	ZESTRA®	U.S.	Word Mark	87882036	4/18/2018	1/15/2019	5653542
Semprae	ZESTRA®	U.S.	Design Mark	87626461	9/28/2017	9/25/2018	5568663
Semprae	ZESTRA®	Algeria	Word Mark	A0081658	12/7/2018	9/22/2019	1426637
Innovus	ZESTRA®	Algeria	Word Mark	DZ/T/2018/002192	4/10/2018	2/20/2020	107383
Semprae	ZESTRA®	Argentina	Word Mark	2701624	9/15/2006	3/18/2010	2352651
Semprae	ZESTRA®	Australia	Word Mark	1846740	5/23/2017	1/18/2018	1846740
Semprae	ZESTRA®	Bahrain	Word Mark	PCT: 1307250	6/23/2016	6/26/2018	1307250
Semprae	ZESTRA®	Brazil	Nominative	828730180	9/14/2006	10/15/2013	828730180
Semprae	ZESTRA®	Canada	Word Mark	1305670	6/16/2006	7/10/2009	743347
Semprae	ZESTRA®	Egypt	Word Mark	PCT: 1307250	6/23/2016	6/23/2016	1307250

Semprae	ZESTRA®	European Union	Word Mark	16966459	7/10/2017	10/8/2018	16966459
Semprae	ZESTRA®	Iran	Word Mark	PCT: 1307250	6/23/2016	6/23/2016	1307250
Semprae	ZESTRA®	Japan	Word Mark	2007099430	9/21/2006	4/11/2008	5126747
Semprae	ZESTRA®	Kuwait	Word Mark	2762	3/26/2019	3/26/2019	1611859
Innovus	ZESTRA®	Lebanon	Word Mark	110112	9/25/2019	10/17/2019	194627
Innovus	ZESTRA®	Malaysia	Word Mark	2017067600	9/13/2017	6/8/2018	2017067600
Semprae	ZESTRA®	Mexico	Word Mark	1139838	12/6/2010	12/12/2011	1257947
Semprae	ZESTRA®	Mexico	Mixed	1920206	7/19/2017	12/13/2017	1834002
Semprae	ZESTRA®	Morocco	Word Mark	PCT: 1307250	6/23/2016	10/20/2017	1307250
Innovus	ZESTRA®	New Zealand	Word Mark	1067338	5/24/2017	11/28/2017	1067338
Semprae	ZESTRA®	Oman	Word Mark	PCT: 1307250	6/23/2016	6/23/2016	1307250
Semprae	ZESTRA®	Peru	Word Mark	724827	10/19/2017	2/14/2018	258933
Innovus	ZESTRA®	Saudi Arabia	Word Mark	197749	8/20/2019	11/12/2019	1440030483
Semprae	ZESTRA®	Tunisia	Word Mark	A0085983	5/14/2019	5/14/2019	1474755
Innovus	ZESTRA®	United Arab Emirates	Word Mark	314049	7/18/2019	7/18/2019	314049
Semprae	ZESTRA®	Qatar	Word Mark	130723	3/27/2019	3/26/2019	130723
Innovus	ZESTRA™	Philippines	Word Mark	42020518293	11/20/2020		
Semprae	ZESTRA™	Turkey	Word Mark	2018/14116	6/23/2018		
Semprae	ZESTRA™	India	Word Mark				
Semprae	适趣液ZESTRA®	China	Word Mark	37637425	4/19/2019	4/19/2019	37637425
Semprae	适趣液ZESTRA™	China	Word Mark	37637897	4/19/2019		
Semprae	ZESTRA BLISS ®	U.S.	Word Mark	85284911	4/4/2011	6/5/2012	4155425
Semprae	ZESTRA ESSENTIAL AROUSAL OILS®	U.S.	Word Mark	87601550	9/8/2017	7/24/2018	5522796
Semprae	ZESTRA ESSENTIAL AROUSAL OILS®	Canada	Word Mark	1424034	1/9/2009	6/12/2012	826098
Semprae	ZESTRA ESSENTIAL AROUSAL OILS®	Turkey	Word Mark	A0092901	12/30/2019	12/30/2019	1512799
Semprae	ZESTRA ESSENTIAL TINGLING OILS®	U.S.	Word Mark	87878279	4/16/2018	12/25/2018	5636940
Semprae	ZESTRA ESSENTIAL TINGLING OILS®	Canada	Word Mark	1531726	6/7/2011	6/9/2014	879658
Semprae	ZESTRA GLIDE®	U.S.	Word Mark	85445196	10/12/2011	1/29/2013	4283722
Semprae	ZESTRA GLIDE®	Australia	Word Mark	1846742	5/23/2017	1/18/2017	1846742

Semprae	ZESTRA GLIDE®	European Union	Word Mark	13011	8/23/2018	8/21/2018	1427413
Innovus	ZESTRA GLIDE®	New Zealand	Word Mark	1067339	5/24/2017	11/28/2017	1067339
Semprae	ZESTRA GLIDE®	Peru	Word Mark	724828	10/19/2017	2/14/2018	258934
Semprae	ZESTRA GLIDE®	Turkey	Word Mark	1514992	12/27/2019	12/27/2019	1514992
Innovus	ZESTRA GLIDE™	Philippines	Word Mark	42020518295	11/20/2020		
Semprae	ZESTRA RUSH®	Turkey	Word Mark	2020/00320	1/3/2020	1/3/2020	2020 00320
Innovus	ZETRUS®	South Korea	Word Mark	40-2019-0146384	9/24/2019	10/26/2020	40-1655710
Innovus	ZETRUS®	South Korea	Korean Characters	40-2019-0131182	8/23/2019	9/21/2020	40-1645138
Aytu Bioscience	ZOLPIMIST®	U.S.	Word Mark	88013915	6/25/2018	3/5/2019	5689515
Aytu Bioscience	ZOLPIMIST®	U.S.	Word Mark	88016434	6/26/2018	2/26/2019	5684905